Adaptive Trials Without The Surprises

Adaptive trials promise greater flexibility, faster decisions, and more efficient drug development, but those benefits can disappear quickly when operations aren’t prepared to adapt. In this Clinical Leader Live, we explore what it takes to execute these studies successfully, including the impact on sites, data, technology, drug supply, study teams, and decision-making, and what sponsors need to anticipate before adaptation turns into disruption. Panelists include Jason Luke (Strand Therapeutics), Sally Tucker (Opus Genetics), and Lori Dodd (NIAID).